Authors/Disclosures
|
Nicolas Dupre, MD, FAAN
(CHU de Quebec - U Laval)
|
Dr. Dupre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea Therapeutics Canada. The institution of Dr. Dupre has received research support from ARSACS Foundation. The institution of Dr. Dupre has received research support from CHUdeQuebec Foundation. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Nicolas Chrestian, MD
|
Dr. Chrestian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Chrestian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Chrestian has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Peer choice. |
|
Steve Verreault, MD
(Hopital De L'Enfant-Jesus)
|
The institution of Dr. Verreault has received research support from BMS. The institution of Dr. Verreault has received research support from Portola. The institution of Dr. Verreault has received research support from Daichii Sankyo. |
|
|
No disclosure on file |
|
Jean-Pierre Bouchard, MD, FAAN
|
No disclosure on file |
|
Guy A. Rouleau, MD, PhD, FAAN
(Montreal Neurological Institute and Hospital)
|
Dr. Rouleau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NovoNordisk. Dr. Rouleau has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for AL-S Pharma. |
|
|
No disclosure on file |